Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Healing I: Introduction01:11

Healing I: Introduction

15
Healing is the physiological process by which the body restores the integrity and function of damaged tissues following injury. It involves a coordinated interplay of cellular proliferation, extracellular matrix remodeling, and growth factor signaling. The extent and nature of the tissue damage determine whether healing occurs by resolution, regeneration, or replacement.ResolutionResolution represents the most complete form of healing, occurring when the injury is minimal and tissue...
15
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

69
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
69
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

57
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal...
57
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

2.4K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.4K
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

50
Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...
50

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of Paediatric-Onset Inflammatory Bowel Disease on Educational Paths and Careers.

Inflammatory intestinal diseases·2026
Same author

Resolution of long-term severe irritable bowel syndrome following fecal microbiota transplantation: A case report and microbiota analysis.

Gut microbes reports·2026
Same author

Disease Course of Eosinophilic Esophagitis Under Anti-inflammatory Treatment.

The journal of allergy and clinical immunology. In practice·2026
Same author

EUS-guided pancreatic duct drainage: a single-center observational study.

iGIE : innovation, investigation and insights·2026
Same author

Role of A2 beta casein in milk-induced eosinophilic oesophagitis: novel in-vivo and in-vitro findings.

Gut·2026
Same author

Evolution of Growth following Anti-Tumor Necrosis Factor-α Therapy in Paediatric Crohn's Disease: Data from the Swiss IBD Cohort Study.

Inflammatory intestinal diseases·2025

Related Experiment Video

Updated: May 5, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

5.6K

Mucosal healing and deep remission: what does it mean?

Gerhard Rogler1, Stephan Vavricka, Alain Schoepfer

  • 1Gerhard Rogler, Stephan Vavricka, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University Hospital Zürich, 8091 Zürich, Switzerland.

World Journal of Gastroenterology
|November 28, 2013
PubMed
Summary

Clarifying terms like "mucosal healing" and "deep remission" in inflammatory bowel diseases (IBD) is crucial. Standardized definitions improve understanding of treatment goals and clinical trial outcomes for IBD patients.

Keywords:
Clinical activityDeep remissionInflammatory bowel diseaseMucosal healingTreatment targets

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.0K
Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
08:52

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

4.0K

Related Experiment Videos

Last Updated: May 5, 2026

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

5.6K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.0K
Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes
08:52

Performing Colonoscopic-Guided Pinch Biopsies in Mice and Evaluating Subsequent Tissue Changes

Published on: February 5, 2021

4.0K

Area of Science:

  • Gastroenterology
  • Clinical Medicine
  • Evidence-Based Medicine

Background:

  • Ambiguous terminology in science, particularly in inflammatory bowel diseases (IBD), leads to confusion.
  • Terms like "mucosal healing" and "deep remission" are critical therapeutic targets but lack consistent definitions.
  • Inconsistent definitions can cause misconceptions regarding treatment goals and clinical trial endpoints in IBD.

Purpose of the Study:

  • To analyze the evolution and current definitions of key terms in IBD treatment.
  • To assess the impact of varying definitions on clinical findings and patient outcomes.
  • To promote clearer and more consistent use of terminology in future IBD research and practice.

Main Methods:

  • Review of existing literature on "mucosal healing" and "deep remission" in IBD.
  • Analysis of the historical development and current usage of these terms in clinical trials and patient care.
  • Synthesis of evidence regarding the clinical significance of achieving these endpoints.

Main Results:

  • Data suggest improved long-term outcomes in IBD patients who achieve mucosal healing.
  • The precise impact of intensified therapies on achieving mucosal healing in patients in clinical remission remains under investigation.
  • Current clinical trials are exploring the benefits of sustained therapeutic interventions.

Conclusions:

  • Standardizing definitions for "mucosal healing" and "deep remission" is essential for advancing IBD treatment.
  • Clearer terminology will enhance the interpretation of clinical trial results and guide daily patient management.
  • Further research is needed to optimize therapeutic strategies based on these endpoints.